SEC Company Response from aTYR PHARMA INC (ATYR) (CIK 0001339970) (ATYR) — Feb 3, 2020
aTYR PHARMA INC (ATYR) (CIK 0001339970)
Date: Feb. 3, 2020 · CIK: 0001339970 · Accession: 0001564590-20-002995
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-235951
Letter
life-corresp.DOCX.htm
aTyr Pharma, Inc.
3545 John Hopkins Court, Suite 250
San Diego, California 92121
February 3, 2020
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: William Mastrianna
Re: aTyr Pharma, Inc.
Registration Statement on Form S-1 (File No. 333-235951)
Request for Acceleration of Effective Date
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, aTyr Pharma, Inc. (the “Company”) hereby requests that the Securities and Exchange Commission (the “Commission”) accelerate the effective date of the above-referenced Registration Statement on Form S-1 (as amended, the “Registration Statement”) and declare the Registration Statement effective as of 4:30 p.m. Eastern time, on February 4, 2020, or as soon thereafter as possible, or at such other time as the Company or its legal counsel, Cooley LLP, may request by telephone to the staff of the Commission. The Company hereby authorizes each of Sean M. Clayton and Alexa M. Ekman of Cooley LLP to make such a request on its behalf.
Once the Registration Statement has been declared effective, please orally confirm that event with Sean M. Clayton of Cooley LLP at (858) 550-6034, or in his absence, Alexa M. Ekman of Cooley LLP at (858) 550-6183.
Sincerely,
aTyr Pharma, Inc.
Show Raw Text
CORRESP 1 filename1.htm life-corresp.DOCX.htm aTyr Pharma, Inc. 3545 John Hopkins Court, Suite 250 San Diego, California 92121 February 3, 2020 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: William Mastrianna Re: aTyr Pharma, Inc. Registration Statement on Form S-1 (File No. 333-235951) Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, aTyr Pharma, Inc. (the “Company”) hereby requests that the Securities and Exchange Commission (the “Commission”) accelerate the effective date of the above-referenced Registration Statement on Form S-1 (as amended, the “Registration Statement”) and declare the Registration Statement effective as of 4:30 p.m. Eastern time, on February 4, 2020, or as soon thereafter as possible, or at such other time as the Company or its legal counsel, Cooley LLP, may request by telephone to the staff of the Commission. The Company hereby authorizes each of Sean M. Clayton and Alexa M. Ekman of Cooley LLP to make such a request on its behalf. Once the Registration Statement has been declared effective, please orally confirm that event with Sean M. Clayton of Cooley LLP at (858) 550-6034, or in his absence, Alexa M. Ekman of Cooley LLP at (858) 550-6183. Sincerely, aTyr Pharma, Inc. By: /s/ Sanjay S. Shukla, M.D., M.S. Sanjay S. Shukla, M.D., M.S. President and Chief Executive Officer